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Abstract: 
Primary Hyperparathyroidism (pHPT) is a common endocrinopathy resulting from 
inappropriately high PTH secretion. It usually results from the presence of a single gland 
adenoma, multiple gland hyperplasia or rarely parathyroid carcinoma. All these conditions 
require different management and it is important to be able to differentiate the underlined 
pathology, in order for the clinicians to provide the best therapeutic approach.  
Elucidation of the genetic background of each of these clinical entities would be of great 
interest. However, the molecular factors that control parathyroid tumorigenesis are poorly 
understood. There are data implicating the existence of specific genetic pathways involved in 
the emergence of parathyroid tumorigenesis. The main focus of the present study is to 
present the current optimal diagnostic and management protocols for pHPT as well as to 
review the literature regarding all molecular and genetic pathways that are be involved in 
the pathophysiology of sporadic pHPT. 
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Introduction:  
Hyperparathyroidism is characterized by hypersecretion of parathyroid hormone (PTH) from 
the parathyroid glands. According to the cause of hypersecretion, hyperparathyroidism can be 
classified as primary, secondary or tertiary. Primary Hyperparathyroidism (pHPT) is a 
common endocrinopathy resulting from inappropriately high PTH secretion from one or more 
enlarged parathyroid glands (1,2). Secondary hyperparathyroidism usually results from low 
vitamin D levels or renal failure, while the tertiary form of the disease occurs when there is 
autonomous hypersecretion from one or more affected glands, despite resolve of secondary 
hyperparathyroidism (2).  
The diagnosis may extend from normocalcemia accompanied by elevated PTH levels to 
hypercalcemia accompanied by elevated or inappropriately normal PTH levels.  The 
incidence of pHPT is estimated to be 3:1000 in the general population and most cases are 
sporadic (3). However, 5%-10% of the patients may be associated with syndromic and 
hereditary disease, like Multiple Endocrine Neoplasia type 1 (MEN1), type 2A (MEN2A), 
type 4 (MEN4) and Hyperparathyroidism Jaw-Tumor syndrome (HPT-JS) or the non-
syndromic familial form of the disease, the Familial Isolated Primary Hyperparathyroidism 
(FIHP) (2,4). 
Almost 90% of the patients are found to have sporadic, non-familial and non-syndromic 
disease (4). Sporadic pHPT is usually caused by a single gland adenoma (85% of patients), 
but may also be caused by hyperplasia of all four glands (10%), double adenomas (2-5%) or 
rarely parathyroid carcinomas (<1%) (1,2). The wide spectrum of disease presentation is very 
important as different management strategies are in demand. 
There are data implicating specific genetic pathways in the emergence of adenomas, 
hyperplasias and carcinomas (5,6), although it seems that epigenetic changes could also 
participate actively in parathyroid tumorigenesis (7,8). The main focus of the present study is 
to present the current optimal diagnostic and management protocols for pHPT as well as to 
review the literature regarding all molecular and genetic pathways that are involved in the 
pathophysiology of sporadic pHPT. 
Diagnosis of pHPT 
The simultaneous presence of persistent hypercalcemia and elevated or inappropriately 
normal PTH levels, makes the diagnosis of pHPT likely (9-11), but not definite and 
alternative benign states such as Familial Hypocalciuric Hypercalcemia (FHH) should be 
excluded (12). FHH is an autosomal-dominant disorder resembling pHPT, which is not cured 
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by surgery (12). The presentation of both disorders may be confusing and the establishment of 
the diagnosis requires a careful and detailed workup. 
Although the clinical presentation of patients with pHPT is heterogeneous and the associated 
symptoms may overlap with those of aging and disease (10), usually patients with 
symptomatic pHPT have overt signs and symptoms; however, the definition of symptomatic 
disease is still evolving. Patients with asymptomatic pHPT have no disease-specific 
symptoms but the diagnosis is always biochemical and well-stated in the latest published 
guidelines on the diagnosis and management of the disease (10,11,13).  
Another aspect of the disease is normocalcemic pHPT, which is an abnormality of the 
relationship between calcium and PTH. Normocalcemic pHPT presents with calcium 
levels within the normal range and the diagnosis could be revealed, with the use of 
calcium loading test: When an oral (or I.V.) load of 1 g elemental calcium or calcium 
gluconate infusion is given, serum ionized calcium concentration increases to 
supranormal values and in normal individuals a PTH suppression is expected (14,15). 
However, in patients with normocalcemic pHPT only a minimal reduction in serum 
PTH concentration is seen (14). The reactivity of PTH to calcium loading could be used 
to establish the diagnosis of normocalcemic pHPT (14-20), as PTH and calcium levels 
may become inappropriate only after the calcium load. 
It is of great importance to adjust the total serum calcium levels not only for albuminemia but 
also for serum protein levels, as hyper- or hypo- proteinemia could lead to false diagnosis (9). 
If the adjusted total serum calcium level is normal, but PTH levels are elevated, then the 
ionized calcium levels could be measured, as pHPT could present with normal total but 
elevated ionized calcium levels (9,11). The ionized calcium measurement should be 
performed in a pH-stable environment, as acidosis or alkalosis could cause respectively 
elevated or suppressed  levels of ionized calcium (21). However, this measurement is of high 
cost and not widely available (11). 
For the diagnosis of pHPT, other states that mimic pHPT should be excluded, such as  FHH 
or medication intake (hydrochlorothiazide or lithium) (11). For the exclusion of FHH, 
calcium to creatinine clearance ratio (CaCrCR) is used and if the ratio is greater than 0.02, 
then the presence of FHH is unlikely, provided that the patient has normal renal function, 
there is not severe calcium or Vitamin D deficiency and the patient is not under treatment 
with loop diuretics (11). In the presence of a CaCrCR <0.02 , the CaSR gene analysis may be 
helpful in establishing the diagnosis of FHH (22). However, it should be taken into account 
that there is high risk of diagnostic confusion between FHH and pHPT, as CaCrCR can 
greatly overlap between both hypercalcemic states (12). In addition, there are other genes 
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involved in FHH, defining three different FHH subtypes (12). FHH type 1 is due to a 
mutation of the CaSR gene, while FHH type 2 and 3 are caused by mutations of GNA11 and 
AP2S2 genes respectively (12). Moreover, another clinical entity that may raise diagnostic 
dilemmas has been recognized, “The Genetically Negative FHH’’, which involves patients 
with an FHH phenotype (hypercalcemia, normal or slightly elevated PTH), no genetic 
abnormality of CaSR, GNA11 and AP2S1 genes, at least one family member with the same 
phenotype and/or failure of surgical removal of parathyroid gland(s) to correct hypercalcemia 
(12). 
Secondary causes for PTH elevation must be meticulously excluded as they mimic 
normocalcemic pHPT (9,11,23),  like malabsorption syndromes, hypercalciuria and certain 
medications such as bisphosphonates, denosumab and loop diuretics. The presence of pHPT 
in children and young adults may be associated with the hereditary/syndromic forms of 
pHPT, however analyzing the hereditary forms of pHPT is beyond the scope of the present 
review. 
Localization of the disease 
Although the diagnosis of pHPT is biochemical, the localization-imaging studies may reveal 
the gland or glands that are affected. Parathyroid imaging is not a diagnostic procedure and is 
advised only if parathyroidectomy (PTx) is planned (9). Once the PTx is decided, localization 
studies are the next step in order to identify the affected gland(s). The most common imaging 
techniques are 
99m
Tc-sestamibi scintigraphy, ultrasound and computed tomography (CT) (24). 
Parathyroid adenomas or multiple gland disease are not always identified and thus, 
parathyroid imaging studies can be negative, but this should not preclude PTx, in specialized 
and experienced endocrine surgeons’ hands (11). 
99m
Tc-sestamibi scintigraphy 
This imaging technique is based on the preferential uptake of 99mTc-sestamibi by the 
mitochondria-rich areas in parathyroid adenomas and hyperplasias (11). Normally 
99m
Tc-
sestamibi uptake is also observed in the thyroid, salivary glands, thymus, mammary gland 
during lactation, liver and bone marrow. This technique is sensitive (90%) and accurate 
(97,2%) for pHPT. There are two different options for 99mTc-sestamibi technique, the single 
isotope washout scintigraphy and the two isotopes- subtraction scintigraphy (
99m
Tc-sestamibi 
and 123I). In the single isotope technique delayed washout is observed in well-defined areas 
indicating the parathyroid hyperfunctioning lesion. In the two-isotope technique there is 
uptake of 99mTc-sestamibi and 123I by the thyroid, and uptake of 99mTc-sestamibi only by the 
parathyroids. The subtraction images may reveal the parathyroid adenoma or multiple gland 
disease. The addition of single-photon emission tomography (SPECT) alone or in 
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combination with low dose computed tomography (CT) usually improves the localization of 
the parathyroid lesion (11). 
Ultrasound 
Normal parathyroid glands are usually not detected by ultrasound. Parathyroid adenomas are 
usually seen as round or oval, hypoechogenic structures, contrasting the hyperechogenic 
thyroid tissue (11). Large parathyroid adenomas may involve calcifications and cysts(11). 
Ultrasound is most useful in identifying adenomas close to the thyroid gland (11).  Ultrasound 
may be useful as an additional study to confirm the localization of a parathyroid adenomas 
identified by 99mTc-sestamibi (11). 
Magnetic resonance imaging (MRI) 
MRI is used less commonly due to its lower sensitivity (50%), however is the imaging of 
choice for pregnant patients. The adenomas appear as a soft tissue mass with high signal 
intensity on T2-weighted frames, but low to moderate in T1-weighted frames (11). The signal 
intensity of the adenoma is enhanced after gadolinium injection on T1-weighted frames, 
compared to normal thyroid tissue. Lymph nodes may have the same appearance (11). 
Computed tomography (CT) 
CT is useful in localizing ectopic mediastinal parathyroid glands with a sensitivity of 
approximately 46–87 %. Another technique that is being used recently with high sensitivity is 
the 4D-CT, with time being the fourth dimension. CT allows rapid assessment of the glands 
but has higher cost, exposure to radiation and requires iodinated contrast agents (11). 
11C-Methionine PET/CT scintigraphy 
This imaging method is not widely available and is rarely used due to its high cost. It is based 
in the uptake and incorporation of the amino acid methionine in the PTH molecule during its 
synthesis (11). 
Selective venous sampling with PTH measurements 
This technique is mainly used in cases of unsuccessful surgery or reoperations. It requires an 
experienced angiographer, it is expensive but has a high sensitivity, almost 75% when 
comparing with 
99m
Tc-sestamibi-SPECT (30%). When all non-invasive techniques have failed 
in revealing the lesion, then selective venous sampling is the imaging of choice in reoperation 
cases (11). 
Management of pHPT 
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The only definitive treatment for pHPT is PTx. Patients with symptomatic pHPT should be 
advised to undergo surgery, unless serious contraindications or significant comorbidities 
exist. However, surgical treatment can also be offered to the asymptomatic patients who meet 
the guideline criteria (age <50, Serum calcium > 1 mg/dL of the upper limit of the reference 
interval, BMD T-score ≤−2.5 at the lumbar spine, femoral neck, the total hip, the distal 1/3 
radius or low-energy fracture, glomerular filtration rate (GFR) of <60 ml/min, 
nephrocalcinosis, renal stones or high stone risk). Table 2 presents the latest guidelines in 
comparison with older ones for the management of asymptomatic pHPT. Data from cohort 
studies demonstrated reductions in the risk of all fractures and renal stone formation post-PTx 
(25-28).  
Cure rates in specialized endocrine surgeons hands exceed 95%, with complications rates as 
low as 1-3%(29). In patients with a single adenoma (85% of patients) surgery can be curative. 
In the 15% of patients with multiple gland disease, the recurrence rate is higher and requires a 
subtotal PTx. Parathyroid carcinoma is rarely (<1%) the cause of pHPT. If a patient is 
suspicious for carcinoma (tumor size > 3 cm, palpable mass, and serum calcium > 14 mg/dL) 
(30), en bloc resection of the ipsilateral thyroid lobe and any invaded tissues should be 
performed (29). 
PTx benefits may also include cardiac and vascular function (31), neurologic and 
gastrointestinal health and most patients report a general clinical improvement (29). The 
complications of PTx are rare and may include failure to cure the disease by not finding the 
affected gland(s), persistence or recurrence of the disease, recurrent laryngeal nerve damage, 
damage in the normal parathyroid glands, bleeding or hematoma and infection. Patients 
should be advised to maintain unrestricted calcium intake and sufficient vitamin D levels 
before surgery in order to avoid hungry bone syndrome. 
Successful preoparative localization of a parathyroid adenoma, is a good indication for 
minimally invasive parathyroidectomy in non-syndromic patients with sporadic pHPT. The 
benefits of this technique are reduced operative time, outpatient surgery, reduced costs, and 
fewer complications (29). As suggested by the latest guidelines, if preoperative imaging has 
not identified a parathyroid adenoma or hyperplasia or if familial disease is highly suspected, 
bilateral neck exploration PTx is preferred (29). A bilateral neck exploration and subtotal PTx 
is usually performed in syndromic patients or in patients with lithium-induced pHPT (11). 
The minimally invasive approach can be extended to a bilateral neck exploration if an 
adenoma cannot be found or if the patient has unsuspected multiglandular disease. 
Multiglandular pHPT may not be excluded before surgery and is seen in almost one in ten 
patients with sporadic pHPT (29) and in these cases bilateral neck exploration is mandatory.  
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Patients with asymptomatic pHPT who do not meet guidelines for surgery or are unable or 
unwilling to undergo PTx may be offered monitoring, with unrestricted calcium intake and 
maintenance of sufficient vitamin D levels. Antiresorptive treatment (bisphosphonates or 
hormone replacement therapy) should be considered in patients with osteoporosis, or in the 
presence of fragility fractures in patients who are unable or unwilling to undergo PTx (11). 
Another option is cinacalcet, a calcimimetic agent, which lowers serum calcium and PTH by 
increasing the sensitivity of the CaSR to extracellular calcium, thereby decreasing serum PTH 
and reducing the renal tubular reabsorption of calcium. With cinacalcet, serum calcium 
normalizes in 70–80 % of patients with pHPT, but fails to normalize PTH in about 50% of 
patients. European Medicines Agency (EMA) and The Food and Drug Administration agency 
of the United States (FDA) have approved the use of cinacalcet for the treatment of secondary 
hyperparathyroidism in patients with chronic kidney disease (CKD) on dialysis, for treating 
hypercalcemia in patients with parathyroid carcinoma and for the treatment of severe 
hypercalcemia in patients with primary HPT who are unable to undergo parathyroidectomy. 
The main disadvantage of this cinacalcet is its high cost and a high incidence of adverse 
reactions, mainly from the gastrointestinal system. It is a useful option in symptomatic 
patients where the disease cannot be controlled by surgical intervention or in circumstances 
where surgery is contraindicated and in patients with unresectable parathyroid cancer (11). 
This drug also does not improve bone mineral density or lower biochemical markers of bone 
turnover (32). There are not sufficient data on its effects on hypercalcemic symptoms, renal 
stones, or quality of life. Treatment with cinacalcet is responsible for urinary calcium 
excretion, either by reduction of tubular calcium reabsorption via the reduction of PTH level, 
or via a direct effect on the calcium sensor receptor located in the upper thick ascending limb 
of the loop of Henle. However, recent studies reported that patients carrying the rs1042636 
polymorphism of the calcium-sensing receptor gene respond more sensitively to cinacalcet 
and have a higher risk of calcium stone formation (33). Data with medical therapy currently is 
short-term and insufficient to justify medical therapy as an alternative to surgery (11).  
Histopathological features of parathyroid neoplasms 
The histological distinction between the various forms of primary hyperparathyroidism is 
challenging as the differential diagnosis between a single adenoma and multiple gland disease 
is difficult. When in sporadic pHPT only one gland is affected, it usually bears only one 
adenoma. However, when multiple glands are involved, they may present a range of 
pathology from diffuse hyperplasia to asymmetric hyperplasia or multiple adenomas. 
Moreover, the histological diagnosis of parathyroid cancer can be challenging and in some 
cases diagnosis can only be done following revelation of distant metastases. However, there 
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are some pathological features that are used for the histological classification of the tumors 
and these features are being analyzed.  
Primary Adenoma 
The incidence of parathyroid adenomas in sporadic pHPT is estimated to be 85-90% (2). They 
are usually single, while multiple affected glands account for 20% of the cases and 
carcinomas for <1% of cases (34). ‘Double’ or ‘multiple’ adenomas may at least in some 
cases alternatively represent multigland hyperplasia, presenting asymmetrically and 
sometimes asynchronously (34). 
Most adenomas are composed of chief cells, a small percentage may be oxyphilic, large clear 
cell adenomas or rarely “water-clear” adenomas or lipoadenomas (35) (34). Typical 
parathyroid adenomas are surrounded by a fibrous capsule, however, microadenomas 
(weighting <0.1 gr) are usually non-encapsulated.  A rim of normal parathyroid tissue is often 
present at the periphery of adenomas, although this feature may not be always present. The 
component cells may be arranged in cords, nests, sheets and follicles and may arrange around 
blood vessels. The round and densely stained nuclei are larger than those present in the non-
neoplastic parathyroid tissue. The nuclei are also hyperchromatic and pleomorphic, the so-
called ‘endocrine atypia’(36). 
The oxyphilic (or oncocytic) adenomas consists mainly of oxyphilic cells and are usually non-
functional. They are usually soft, ellipsoid or lobulated with variable brownish colors. 
Microscopically, oxyphilic adenomas are composed of sheets, anastomosing cords and acinar 
arrangement of polygonal cells with abundant granular, brightly eosinophilic cytoplasm and 
centrally placed rounded nuclei (35). 
The large clear cell (light chief cell) adenoma is another rare variant of adenoma, they are 
comprised of polygonal cells with cytoplasmic vacuoles filled with glycogen. They exhibit 
positivity in Periodic Acid-Schiff (PAS) staining, with or without diastase digestion. The 
water-clear cell adenoma consists of nests and acini with clear cells containing abundant 
foamy, granular cytoplasm and mild nuclear pleomorphism. They are thought to be large clear 
cell adenomas with glycogen accumulation rather than true water-clear cells with membrane 
bound vesicles. Lipoadenomas have also been described and are characterized by nests and 
cords of chief cells with a few oxyphil cells intimately admixed with variable amount of 
mature adipose tissue and fibrous stroma (34). They may be non-functional or rarely may 
present with primary hyperparathyroidism(35). 
It should also be mentioned that there are tumors with some features suggesting malignancy, 
but falling short of unequivocal histological diagnosis of malignancy, which are termed 
“atypical adenoma”. The usual histopathological features include fibrous bands, pronounced 
trabecular growth, remarkable mitotic activity (> 1 mitosis per 10 high- power fields), tumor 
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necrosis and incomplete invasion of the capsule. The significance of the remarkable mitotic 
activity is unclear. Their detection should prompt careful assessment, while searching for 
other features of malignancy (34).  
 
Primary Hyperplasia- Multiple Gland Disease 
Parathyroid hyperplasia usually affects 10-15% of sporadic cases with pHPT. It involves may 
be diffuse or asymmetrical and involve some glands (34,37). Asynchronous presentation may 
also occur (34). The glands are enlarged, hypercellular and functioning with decreased or 
absent intracellular fat, as indicated by fat staining (38). The glands may demonstrate diffuse 
proliferation of parenchymal cells, with little or no extracellular fat or nodular development 
consisting mainly by chief cells, although foci of oncocytes and clear cells may be admixed 
(37).  
There are two major types of histological hyperplastic proliferation patterns. One is the chief 
cell hyperplasia pattern and the other is the clear cell hyperplasia pattern. The above variation 
implies that there are different molecular pathways that lead to the development of 
hyperplastic multiple gland disease. Primary chief cell hyperplasia may be observed 
predominantly in sporadic but also in hereditary forms of pHPT.  
Hyperplasia occurs predominantly in chief cells in this histological subtype. Gland 
enlargement can by either symmetrical or asymmetrical occurring only in some glands. Of 
interest is the fact that although within a single gland the growth pattern is usually diffuse, in 
some cases it presents with a nodular intraglandular pattern of growth with foci of normal 
parathyroid tissue. The latter is seen in hereditary disease, usually Multiple Endocrine 
Neoplasia type I, suggesting formation of multiple adenomas involving all glands rather than 
true diffuse hyperplasia in these patients.  
Water cell hyperplasia is rare and is never associated to hereditary disease. In this entity all 
glands are diffusely pathologic (36). 
 
Parathyroid carcinoma 
Parathyroid carcinoma is a rare lesion whose histological diagnosis could be challenging. It 
may require the presence of distant metastasis in order to confirm the diagnosis. Histological 
findings could include those seen in atypical adenomas with some additional evidence of 
invasion. Abnormal mitotic activity appear to be a feature, but not pathognomonic of this 
entity. The World Health Organization suggests that the following criteria must be fulfilled in 
order to confirm the diagnosis: presence of vascular invasion (in the capsule or adjacent 
tissues), capsular invasion with extension to adjacent tissues and/or presence of metastases. 
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Recently, De Lellis mentioned that most carcinomas have a solid growth pattern with tumor 
cells arranged in diffuse masses, small nests, or trabeculae, some tumors exhibiting spindle 
cell, follicular or papillary patterns (39,40). There is no variation in nuclear size and shape 
and this may be an indistinguishable feature from adenomas. Some tumors exhibit 
pleomorphism with coarse chromatin and macronucleoli, a feature that must be distinguished 
from the so-called endocrine atypia encountered in parathyroid adenomas and other benign 
endocrine tumors (39). 
 
Molecular pathways and genetic involvement in sporadic pHPT 
Tumorigenesis may involve multiple different mechanisms responsible for hyperplastic 
changes such as activation of oncogenes, inactivation of tumor-suppressor genes, imbalance 
between growth factors and proteins involved in cell regulation and epigenetic alterations 
(41,42). Genes involved in these processes that have been associated with sporadic pHPT are 
analyzed below. 
 
Pathways and genes involving cell cycle regulators 
The cell cycle is a series of events that take place in the cell and lead to its division. Cyclins 
are proteins that are involved in the regulation of progression of cells through the cell cycle 
and activate cyclin-dependent kinases (CDKs)(43). The expression of cyclin genes regulates 
the activity of CDKs (43). Elevated levels of cyclin D1 (CCND1, PRAD1) have been shown 
to promote cell cycle progression. CCND1 gene has been found to be overexpressed in 
sporadic parathyroid adenomas and carcinomas (43-45). On the other hand, CDK inhibitors 
also regulate cellular proliferation and apoptosis, by inhibiting the complex cyclin-CDK (43). 
CDK inhibitor 1B (P27, CDKN1B) and CDK inhibitor 1A (P21) are members of the CDK 
inhibitor proteins. Studies have shown that sporadic parathyroid carcinomas have decreased 
P27 and P21 expression (43), while low frequency germline and somatic mutations have also 
been reported in patients with adenomas (46-48). CCND1 gene has been found to be 
overexpressed in sporadic parathyroid adenomas and carcinomas (43-45). 
Another inhibitor of cell cycle progression is retinoblastoma protein (RB). It works as a tumor 
suppressor factor. Allelic Loss of the RB gene was found to be involved in parathyroid 
carcinomas (25).  Proliferating Cellular Nuclear Antigen (PCNA) has been studied and shown 
to interact with other proteins involved in DNA replication and repair, cell cycle control, 
chromatin remodeling/epigenetic inheritance, chromatid cohesion, and transcription (49). 
PCNA acts as a cofactor for DNA polymerase D and interacts with cyclin D1 (49,50). It was 
recently demonstrated that  PCNA was considerably higher in adenomas, followed by primary 
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hyperplasias, whereas PCNA in common adenoma and other hyperplastic changes were even 
lower than in healthy parathyroid glands (51,52).  
Recent studies showed that about 40-45% of sporadic parathyroid tumors show MEN1 gene 
mutations. Sporadic parathyroid tumors harboring MEN1 gene somatic mutations frequently 
evidence LOH on chromosome region 11q13 (53-55). Targeted inactivation of MEN1 gene 
specifically to the parathyroid glands resulted in parathyroid neoplasia accompanied by 
hypercalcemic hyperparathyroidism  (56). Loss of heterozygosity of chromosome 11q, the 
genomic location of the MEN1 gene, is the most frequent genomic aberration found in 
parathyroid adenomas (56). The product of MEN1 gene, called menin can function as 
suppressor of transcription, because this protein is able to bind a family of transcription 
factors such as AP-1/Jun-Fos family, and it is also associated with a histone methyltransferase 
(HMT) complex leading to an increased expression of cyclin-dependent kinase inhibitors 
(CDKIs) and consequently suppressing cell growth (57,58).  
Latest data on sporadic pHPT have concluded on specific genes being up- or downregulated, 
mostly on sporadic adenomas (4). Non-familial pHPT patients (almost 90% of patients with 
pHPT), may carry somatic mutations in specific genes like MEN1, CCND1, RB, RIZ1, 
CTNN3 and LRP5 genes (4). However, sporadic forms of pHPT may also be associated with 
germline mutations involving MEN1, CDC73, CaSR, CDKIs or PTH genes (4). It is 
estimated that 10% of patients presenting with sporadic pHPT under the age of 45, carry a de 
novo germline mutation in MEN1, CDC73 or CaSR genes (4,59,60). In addition, almost 5% 
of patients with pHPT presenting in the sixth to ninth decades of life with a single adenoma 
and without family history of parathyroid disease, MEN or other endocrine tumor syndromes, 
may carry germline mutations of the CDKI genes [usually involving CDKN1A (p21), 
CDKN2B (p15) or CDKN2C (p18)] (4,61). A PTH nonsense mutation, Arg83Stop, has also 
been associated with hypercalcemia due to parathyroid adenoma and an undetectable PTH 
(62).  
 
Wnt/β-catenin signaling pathway and genetic alterations causing its dysfunction in pHPT  
Another important pathway that should be mentioned is the Wnt/β-catenin signaling pathway, 
which affects multiple cellular functions mainly through gene transcription. Dysregulation of 
this pathway with subsequent accumulation of β-catenin in the cell cytoplasm or nucleus has 
been implicated in carcinogenesis (48). When cells bind a Wnt-ligand, the protein binds to 
frizzled receptors, LRP5/6 co-receptors and a destruction complex (for example APC, Axin, 
GSK-3b, Dvl). This binding causes Axin dephosphorylation and degradation and the 
production of the non-phosphorylated and active β-catenin. The latter binds to the LEF/TCF 
family of transcription factors and regulates gene transcription (48). Mutant proteins of the 
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Wnt pathway have been associated with some forms of cancer. Stabilizing β-catenin 
mutations and resistance to cytoplasmic dephosphorylation and degradation, causes 
accumulation of non-phosphorylated active β-catenin and have been associated with 
parathyroid tumorigenesis and pHPT (48,63). In addition, the absence of stabilizing mutations 
of beta-catenin encoded by CTNNB1 exon 3 has been reported in a large series of sporadic 
parathyroid adenomas (64). 
 Two low frequency β-catenin stabilizing mutations have been identified and reported in 
parathyroid adenomas [Ser37Ala (48,63) and Ser33Cys (63,65,66)], but more studies are 
required to substantiate this genetic disorder. In parathyroid adenomas without a stabilizing β-
catenin mutation, the accumulation of the protein may also be due to an aberrantly spliced 
internally truncated Wnt receptor LRP5 (LRP5∆). This disabled receptor was found to be 
expressed in 86% of the investigated parathyroid adenomas causing pHPT (67). In some 
investigated parathyroid adenomas the MYC oncogene was found to be overexpressed and 
regulated by β-catenin activity in a human parathyroid cell line, as was expression of the 
CCND1 oncogene (68,69). 
 
Pathways involving growth factors and reported genetic predisposition to pHPT. 
Growth factors can affect cellular growth, proliferation, tissue repairing and homeostasis and 
any imbalance could lead to tumorigenesis (43). Angiogenesis is a key process for the 
emergence and survival of proliferative lesions, as it involves the formation of new vessels 
from existing ones to ensure that oxygen and other necessary nutrients will be transferred to 
the tumor. Factors that are found to be overexpressed in pHPT include vascular endothelial 
growth factor (VEGF), fibroblast growth factor (FGF), transforming growth factor beta 
(TGFβ) and insulin growth factor-1 (IGF-1) (43). Genes affecting growth factor expression 
are found to be involved in sporadic pHPT. 
VEGF is regulating angiogenesis in normal or pathological states. It is implicated in 
tumorigenesis and in parathyroid proliferating lesions it has a proangiogenic effect (43). Basic 
FGF (FGF-2) is also found to be upregulated in parathyroid tumors (70). FGF-2 is involved 
both in cell cycle regulation as well as in angiogenesis, tissue growth and repair (43,71). FGF-
2 and VEGF act synergistically on angiogenesis in cultured epithelial cells (71,72). TGFβ is 
found to affect multiple cellular processes, including angiogenesis, and it is increased in 
patients with pHPT (73). In low dosage, it acts in favor of cell proliferation, while in high 
dosage it inhibits proliferation (43). IGF-1 is the effector for the action of growth hormone. It 
is also a mediator of parathormone anabolic effects on bones. It is found to stimulate cellular 
proliferation and it is implicated in the growth regulation of parathyroid tumors (74). 
 
Apoptotic pathways and genetic factors involved in pHPT 
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Apoptosis is a form of programmed cell death which ensures the tissue homeostasis and the 
maintenance of certain number of cells (75). Mechanisms involved in the pathogenesis of 
pHPT include also an imbalance between apoptotic and anti-apoptotic factors, some of which 
are Tumor Necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), Fas receptor, 
the BCL family, the mouse double minute 2 homolog (MDM2) and tumor protein 53 (p53) 
(43,75). 
TRAIL is a protein that induces caspase 8-dependent apoptosis, via death receptors DR4 and 
DR5 (75). It has been implicated in anticancer activity and cardiovascular disease prevention, 
lipid uptake and blood vessel homeostasis (75-79). However, TRAIL can have an opposite 
role in apoptosis when forming complexes with transmitters such as Fas-associated with a 
death domain (FADD) or caspase-8 (80,81). TRAIL gene has been found to be overexpressed 
in parathyroid adenomas and hyperplasias compared to normal tissue (43). 
Fas receptor is a death receptor causing apoptosis by forming the death-inducing signaling 
complex (DISC) (75). Parathyroid adenomas and hyperplasias demonstrated overexpression 
of the FAS gene compared to normal tissue. Hyperplasias showed the highest expression, 
whereas in adenomas, the expression of the FAS gene was increased compared to normal 
tissue, but it was lower than in hyperplasias (41). 
The BCL-2 is a family of proteins that regulates caspase activation and mitochondrial outer 
membrane permeabilization (43). The anti-apoptotic BCL-X(L) and BCL-W genes were 
higher in adenomas compared to hyperplasias (43). The expression of pro-apoptotic members 
of the BCL-2 family, like BIM and BOK, was decreased in both adenomas and hyperplasias 
(43). Mutations in the BIM gene may lead to resistance to apoptosis (43). MDM2 is a 
negative regulator of the tumor suppressor p53, acts as an oncogene and it is found to be 
overexpressed in multiple tumor types like sarcomas and breast cancer (43). It seems that 
BCL-2 and MDM2 have no expression in parathyroid carcinoma, while they are expressed in 
adenomas and hyperplasias (41,43). In addition, p53 was found to be overexpressed in 
parathyroid carcinomas, Fas and p53 expression is correlated in hyperplasia, while there is no 
relation between Fas, Ki-67 and PCNA (43,82). 
There are a few recent studies trying to set the genetic background of primary parathyroid 
hyperplasia versus adenoma via the differential gene expression profile (83-86). Data from 
one study revealed more than 200 genes being differentially expressed among hyperplasia and 
adenoma (85). The most statistically significant ones being upregulated were the Hook 1 
protein, the thromboxane A2 receptor gene (TBXA2R) and the fragile histidine triad gene 
(FHIT) (85). The downregulated genes were the prostaglandin-d synthase gene (PTGDS) and 
EGFR (downregulated in hyperplasia) (85). All referred genes are listed in Table 1.   
 
MiRNA differential expression and parathyroid tumorigenesis. 
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MicroRNAs (miRNA) are small non-coding, single-stranded RNAs, 19-25 nucleotides long, 
which exert regulatory functions such as regulation of gene expression through multiple 
mechanisms including decreased translation, increased degradation of the target messenger 
RNA (mRNA), or both (8). Binding of miRNA to its target mRNA results in repression of 
translation (8). MiRNA genes may act as oncogenes or tumor suppressor genes (87). 
Differentially expressed miRNAs have been reported in parathyroid adenomas and 
carcinomas, compared to normal parathyroid tissue (88). Recent data suggest a specific 
expression pattern of miRNAs in parathyroid carcinoma (2,89). Among the down-regulated 
miRNAs, miR-296, miR-139, miR-126-5p, miR-26b and miR-30b are differentially expressed 
in parathyroid carcinomas (2, 82). However, there are limited data on miRNA expression 
profile in the so-called sporadic primary hyperplasia (2), compared to parathyroid adenoma or 
carcinoma. Rahbari et al. suggested the existence of 22 uniquely expressed miRNA in 
parathyroid hyperplasia which need to be validated in other cohorts as well (2). 
Summary-Clinical implications: 
Sporadic pHPT is a common clinical entity with many of its aspects needed to be elucidated. 
It would be of great interest to investigate further the genetic deregulation of parathyroid 
tumors, as it may provide new aspects in the earlier and accurate pre-operational diagnosis 
and management. The clarification of the molecular pathways affecting parathyroid 
tumorigenesis will elucidate the pathogenetic mechanisms and will probably suggest new 
therapeutic approaches, targeting in the repression of deregulation of the affected pathways.    
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FIGURE 1. Parathyroid tumorigenesis mechanisms via the cyclins pathway. 
CCND1 gene, encoding Cyclin D1, is upregulated in parathyroid adenomas. MEN1 gene 
inactivation results in a reduction of P27 and inhibition of Cyclin and CDK 
complexes, as well as a loss of control of cell cycle progression. Inactivating somatic 
and germline mutations of CDC73 are frequently identified in patients with 
parathyrooid carcinoma. CDKN1B has been reported to be downregulated in 
adenomas compared to normal tissues. 
Page 22 of 25
TABLE 1. Genes reported to be involved in sporadic pHPT. 
 
Genes Adenoma 
Multiple 
Gland Disease 
Carcinoma 
C
e
ll
 C
y
c
le
 R
e
g
u
la
to
r 
G
e
n
e
s 
CCND1 ✓  ✓ 
P27  ✓  ✓ 
P21 ✓  ✓ 
P18 ✓   
P15 ✓   
PCNA ✓ ✓  
RB   ✓ 
MEN-1 ✓   
RIZ1 ✓   
CTNN3 ✓   
LRP5 ✓   
CDC73 ✓  ✓ 
CaSR ✓   
PTH ✓   
W
n
t/
β
-
c
a
te
n
in
 
p
a
th
w
a
y
  CTNNB1 ✓   
LRP5∆ ✓   
MYC ✓   
CCND1 ✓   
A
p
o
p
to
ti
c
 F
a
c
to
r
s 
TRAIL ✓ ✓ ✓ 
FAS ✓ ✓ ✓ 
BCL-X(L) ✓   
BCL-W ✓   
BCL-2  ✓ ✓  
MDM2 ✓ ✓  
P53  ✓ ✓ 
ΤΒΧΑ2R  ✓  
FHIT  ✓  
PTGDS  ✓  
EGFR  ✓  
G
r
o
w
th
 
F
a
c
to
r
s 
VEGF ✓ ✓ ✓ 
FGF ✓ ✓ ✓ 
TGFβ ✓ ✓ ✓ 
IGF-1 ✓ ✓ ✓ 
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TABLE 2. Evolution of Guidelines Criteria for Surgical Management of 
asymptomatic pHPT throughout the years 1990-2016. 
Year 1990
a 
2002
b 
2008
c 
2014
d 
2016
e 
Age <50 <50 <50 <50 <50 
Calcium 
Levels 
1-1,6 mg/dl the 
upper limit or    
life-threatening 
hypercalcemia 
>1 mg/dl the 
upper limit 
>1 mg/dl the 
upper limit 
>1 mg/dl the 
upper limit 
>1 mg/dl the upper 
limit or >0.12 
mmol/L for Ca2+. 
Renal 
Function 
eGFR reduction > 
30% 
eGFR 
reduction > 
30% 
eGFR < 60 
ml/min 
eGFR < 60 
ml/min 
eGFR < 60 ml/min 
Urine 
calcium 
excretion 
>400 mg/dl >400 mg/dl 24h urine for 
calcium not 
recommended 
>400 mg/dl >400 mg/dl 
Osteoporosis Z-Score <-2,0 
(forearm) 
T-Score <-2,5 
(any site) 
T-Score <-2,5 
(any site) 
and/or 
fragility 
fracture 
T-Score <-2,5 
(lumbar spine, 
total hip, femoral 
neck, or distal 
radius) and/or 
fragility fracture 
diagnosed by 
imaging 
 
T-score ≤−2.5 
(lumbar spine, 
femoral neck, total 
hip, or the 1/3 
radius) for 
postmenopausal 
women or males 
>50 yrs. A 
prevalent low-
energy fracture, 
which requires a 
routine X-ray of 
the thoracic and 
lumbar spine (or 
vertebral fracture 
assessment by 
DXA). 
Other Kidney stones 
detected by 
abdominal 
radiograph 
  Presence of 
nephrolithiasis or 
nephrocalcinosis 
by x-ray, 
ultrasound, or CT 
Presence of 
nephrolithiasis, 
nephrocalcinosis 
or increased stone 
formation risk. 
eGRF= estimated Glomerular Filtration Rate 
a
 Diagnosis and management of asymptomatic primary hyperparathyroidism. National Institutes of Health Consensus Development 
Conference. October 29-31, 1990. Consensus Statement. 1990 Oct 29-31;8(7):1-18 
b 
Bilezikian JP et al, 2002 Summary Statement from a Workshop on Asymptomatic Primary Hyperparathyroidism: a Perspective for 
the 21st Century. J Bone Miner Res 17: Suppl 2: N2-11. 
c
 Bilezikian JP, Khan AA, Potts JT Jr, 2009 Guidelines for the management of asymptomatic primary hyperparathyroidism: 
summary statement from the third international workshop. J Clin Endocrinol Metab 94: 335-339. 
d 
Bilezikian J.P., et al. J Clin Endocrinol Metab. 2014 Oct;99(10):3561-9. 
e
 Khan A et al. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian 
and international consensus. Osteoporosis International 2017; 28:1-19 
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FIGURE 1. Parathyroid tumorigenesis mechanisms via the cyclins pathway.  
CCND1 gene, encoding Cyclin D1, is upregulated in parathyroid adenomas. MEN1 gene inactivation results in 
a reduction of P27 and inhibition of Cyclin and CDK complexes, as well as a loss of control of cell cycle 
progression. Inactivating somatic and germline mutations of CDC73 are frequently identified in patients with 
parathyrooid carcinoma. CDKN1B has been reported to be downregulated in adenomas compared to normal 
tissues.  
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